Preliminary guidance on safety data collection for COVID-19 vaccine safety

This deliverable provides guidance on the collection of safety data for COVID-19 vaccine candidates. This includes a brief discussion of the types of safety data to collect in trials, a sample memory aid template for collection of solicited local and systemic reactions with guidance re: data analysis and presentation, a literature search on enhanced disease and a report of the consensus conference on enhanced disease following immunization.

See Below document to download SO2-D2.4_Preliminary guidance on safety data collection for COVID-19 vaccine safety_V1.0

 

Loader Loading...
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab

More SAFETY TEMPLATES

Live-attenuated viral vaccines: standardized template for collection of key information for benefit-risk assessment

October 13, 2023

Viral vector vaccines: standardized template for collection of key information for benefit-risk assessment

October 13, 2023

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment

October 13, 2023

Modified Vaccinia Ankara (MVA) vaccine platform: standardized template for collection of key information for risk/benefit assessment

October 4, 2023

Medigen COVID-19 protein vaccine: standardized template with key considerations for a benefit/risk assessment

April 6, 2023

Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment

August 19, 2022
View All

More Posts

Email:
bc-coordinator@taskforce.org

Address:
The Task Force for Global Health,
330 W. Ponce de Leon Ave.
Decatur, GA 30030

Linkedin

© Brighton Collaboration  2023. All rights reserved.